ReviewMicrobial biotechnology2019
Novel bioactive natural products from bacteria via bioprospecting, genome mining and metabolic engineering.
Review in Microbial biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- Evolutionary diversification of polyketide synthase (PKS) enzymes in Monascus purpureus strains for exploitation as a molecular factory.Archives of microbiology · 2026Article
- Heterologous Expression and CRISPR/Cas9-Assisted Manipulation of the Hybrid Gene Cluster Specifying the Biosynthesis of Meroterpenoids and Phenazines.ACS synthetic biology · 2026Article
- Antioxidant potential and genomic adaptation ofFrontiers in microbiology · 2026Article
- Whole-genome characterization of halotolerant Enterobacter roggenkampii OSNO4 and its potential for climate-resilient agriculture.PloS one · 2026Article
- Discovery of acylsulfenic acid-featuring natural product sulfenicin and characterization of its biosynthesis.Nature chemistry · 2025Article
- Karakum desert: a unique source of cultivable novel and rare actinomycetes with a remarkable biosynthetic potential.World journal of microbiology & biotechnology · 2025Article
- Current Approaches and Implications in Discovery of Novel Bioactive Products from Microbial Sources.Current microbiology · 2025Review
- Bioprospecting Marine Fungi from the Plastisphere: Osteogenic and Antiviral Activities of Fungal Extracts.Marine drugs · 2025Article
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Secondary Metabolite Biosynthesis Potential ofACS omega · 2025Article
- Genome Mining Analysis Uncovers the Previously Unknown Biosynthetic Capacity for Secondary Metabolites in Verrucomicrobia.Marine biotechnology (New York, N.Y.) · 2024Article
- Employing Bacillus and Pseudomonas for phytonematode management in agricultural crops.World journal of microbiology & biotechnology · 2024Review
- A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs.Cancers · 2024Review
- Total Synthesis of the Phenylnaphthacenoid Type II Polyketide Antibiotic Formicamycin H via Regioselective Ruthenium-Catalyzed Hydrogen Auto-Transfer [4 + 2] Cycloaddition.Journal of the American Chemical Society · 2024Article
- Exploring the secrets of marine microorganisms: Unveiling secondary metabolites through metagenomics.Microbial biotechnology · 2024Review
- Culture-dependent identification of rare marine sediment bacteria from the Gulf of Mexico and Antarctica.bioRxiv : the preprint server for biology · 2024Article
- New investigation of encoding secondary metabolites gene by genome mining of a marine bacterium, Pseudoalteromonas viridis BBR56.BMC genomics · 2024Article
- Biosynthetic potential of the sediment microbial subcommunities of an unexplored karst ecosystem and its ecological implications.MicrobiologyOpen · 2024Article
- Unlocking the potential of bacterial endophytes from medicinal plants for drug discovery.Microbial biotechnology · 2024Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For over seven decades, bacteria served as a valuable source of bioactive natural products some of which were eventually developed into drugs to treat infections, cancer and immune system-related diseases. Traditionally, novel compounds produced by bacteria were discovered via conventional bioprospecting based on isolation of potential producers and screening their extracts in a variety of bioassays. Over time, most of the natural products identifiable by this approach were discovered, and the pipeline for new drugs based on bacterially produced metabolites started to run dry. This mini-review highlights recent developments in bacterial bioprospecting for novel compounds that are based on several out-of-the-box approaches, including the following: (i) targeting bacterial species previously unknown to produce any bioactive natural products, (ii) exploring non-traditional environmental niches and methods for isolation of bacteria and (iii) various types of 'genome mining' aimed at unravelling genetic potential of bacteria to produce secondary metabolites. All these approaches have already yielded a number of novel bioactive compounds and, if used wisely, will soon revitalize drug discovery pipeline based on bacterial natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.